Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment

Cannabis Intoxication Clinical Trial

Official title:

Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03994926
• Other study ID #: 131310
• Status: Terminated
• Phase: Early Phase 1
• Start date: February 3, 2020
• Est. completion date: March 13, 2020

Study information

• Verified date: September 2021
• Source: Battelle Memorial Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if an eye tracking impairment sensor can detect cannabis-induced impairment after using cannabis.The overall objective is to correlate measures collected from the eye tracking sensor with measures related to cannabis impairment (e.g., plasma THC levels, self-reported cannabis subjective effects, cognitive effects).

Description:

The proposed project is a single-visit clinical laboratory study to evaluate the initial efficacy of an eye tracking sensor to detect cannabis-related impairment. Participants will be experienced but not frequent cannabis users without evidence of heavy alcohol or illicit drug use or other physical or mental health illness. Participants will come in for one screening visit, and those who consent, are eligible, and enroll will complete one experimental laboratory session involving smoking of 50% of 1 active (approximately 4.0% THC) cannabis cigarette. Assessments will be collected after-cannabis smoking up to 4 hours. Participants will be sent home from the laboratory via taxi.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: March 13, 2020
• Est. primary completion date: March 13, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Willing to sign a confidentiality agreement stating the will not discuss study specifics, information or materials presented to them in the study with those not involved in the study;

2. Currently living in Baltimore City or Baltimore County, MD, or Investigator discretion;

3. Able to read, understand, and sign informed consent;

4. 18-55 years old;

5. Self-reports lifetime smoking of cannabis at least 10 times without any negative side effects;

6. Self-reports past-year smoking of cannabis at least 1 time but no more than 2 days per week on average;

7. Designation of Medically Healthy for Research by the Study Physician.

8. Agree to abstain from consuming alcohol for 10 hours and marijuana for 72 hour prior to the study visit

Exclusion Criteria:

1. BAC > 0.020% as measured by alcohol breathalyzer;

2. Meets DSM-5 criteria for any current Axis I disorder other than mild or moderate Cannabis Use Disorder;

3. Self-reported current desire to stop cannabis use, defined as 7 or greater on an 11-rung (scale of 0-10) on the Contemplation Ladder assessment;

4. Self-reported current asthma, chronic obstructive pulmonary disease, hypertension, cardiovascular disease or any other medical illness that precludes participation based on the clinical judgment of the Study Physician and Investigative Team;

5. Has difficulties with blood draws or poor venous access;

6. History of blood donation in the past 30 days or receiving blood products within the past 2 months prior to any experimental visit;

7. Investigator discretion due to self-reported use of medical cannabis or using cannabis for self-medication;

8. Among females, current pregnancy or lactation or attempting to get pregnant, or at risk of becoming pregnant, as defined as being sexually active with a male partner and not willing to use a reliable form of contraception;

9. Investigator discretion due to use of caffeine, over-the-counter (OTC) drugs, prescription drugs, alcohol, or physical/mental health history;

10. Positive urine drug screen for drugs included on the urine drug panel other than cannabis;

11. Acute illness (such as cold or flu) which will require participant to be rescheduled, if authorized by study PI;

12. Vital signs thought to be clinically significant by licensed medical professional;

13. Self-reported history or medical evidence of prior intravenous drug use; and

14. Investigator discretion due to medical, mental health, or substance use history.

15. Presence of implanted devices in the body (pacemaker etc)

16. Previously reported negative effects from the use of VR goggles or negative effects from the use of VR goggles during screening

Related Conditions & MeSH terms

• Cannabis Intoxication
• Marijuana Abuse

Intervention

Device:
• Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye
Device measures smooth eye pursuit and response to light flash after pt smokes cannabis

Drug:
• Cannabis cigarette - 4.0% THC
smoked cannabis 4.0% THC

Locations

Country	Name	City	State
United States	Battelle Memorial Institute	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Battelle Memorial Institute

Country where clinical trial is conducted

United States, 

References & Publications (4)

Casswell S, Marks D. Cannabis induced impairment of performance of a divided attention task. Nature. 1973 Jan 5;241(5384):60-1. — View Citation

Desrosiers NA, Ramaekers JG, Chauchard E, Gorelick DA, Huestis MA. Smoked cannabis' psychomotor and neurocognitive effects in occasional and frequent smokers. J Anal Toxicol. 2015 May;39(4):251-61. doi: 10.1093/jat/bkv012. Epub 2015 Mar 4. — View Citation

Murillo R, Crucilla C, Schmittner J, Hotchkiss E, Pickworth WB. Pupillometry in the detection of concomitant drug use in opioid-maintained patients. Methods Find Exp Clin Pharmacol. 2004 May;26(4):271-5. — View Citation

Pickworth WB, Rohrer MS, Fant RV. Effects of abused drugs on psychomotor performance. Exp Clin Psychopharmacol. 1997 Aug;5(3):235-41. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in Pupil Dilation	Change in pupil dilation in different lights will be measured by the eye tracking sensor	Before and after smoking (up to 240 minutes)
Primary	Change from baseline in Gaze Nystagmus	Change in Gaze Nystagmus will be measured by the eye tracking sensor	Before and after smoking (up to 240 minutes)
Primary	Change from baseline in Lack of Convergence	Change in Lack of Convergence will be measured by the eye tracking sensor	Before and after smoking (up to 240 minutes)
Secondary	Plasma THC	Plasma concentration before and after smoking	Before and after smoking (9 timepoints up to 240 minutes post smoking)
Secondary	Change from baseline in Cannabis Subjective Effects	Scores for the question "do you feel a drug effect" are measured on a 0-100 point visual analogue scale to measure change in marijuana intoxication across timepoints.	Before and after smoking (up to 240 minutes post smoking)
Secondary	Change from baseline in Four Choice Reaction Time Task	Will assess changes in psychomotor/cognitive performance known to be sensitive to the acute effects of smoked cannabis.	Before and after smoking (up to 240 minutes post smoking)
Secondary	Change from baseline in Digit Symbol Substitution Task	Will assess changes in psychomotor/cognitive performance known to be sensitive to the acute effects of smoked cannabis.	Before and after smoking (up to 240 minutes post smoking)